Retroperitoneal Sarcoma Surgery
A retroperitoneal sarcoma is cured by one well-planned operation more than by any drug. This guide covers liposarcoma and leiomyosarcoma, needle biopsy before surgery, removing nearby organs en bloc, what the STRASS trial found on radiotherapy and a three to four week stay in Istanbul.
About This Department
The first operation is the best chance to cure a retroperitoneal sarcoma. One piece, one margin, done right the first time.
Retroperitoneal sarcomas grow silently at the back of the abdomen, and in one large surgical series the median tumor measured 17 cm. Surgery is the only treatment that cures them, and the extent of that first operation shapes the risk of the tumor coming back more than any drug or radiation. In a combined series of 1,007 patients from eight European and North American reference centers, five-year overall survival after resection was 67 percent.
A large mass behind the bowel, found on a scan done for something else. Many come to light this way.
What happens next matters.
If a surgeon offers to remove a retroperitoneal mass before a biopsy has confirmed what it is, ask for a sarcoma center review first. A tumor shelled out in pieces cannot be put back, and a second operation rarely repairs that start.
Types of retroperitoneal sarcoma
Subtype decides how the tumor behaves, where it comes back, and how wide the operation should be.
Liposarcoma
The commonest type, made of fat-like cells.
Well-differentiated
Slow-growing and almost never spreads to other organs, but it can blend into the normal fat around it and return in the same place years later.
Dedifferentiated
A more aggressive area inside a liposarcoma, with a higher risk of local return and of spread.
Leiomyosarcoma, which grows from smooth muscle and often from the wall of the vena cava, behaves differently. In the 1,007-patient series, published in the Annals of Surgery in 2016, patterns of recurrence varied clearly by subtype, and tumor size, grade, multifocality and completeness of resection all predicted outcome. Leiomyosarcoma spreads mainly through the blood to the lungs and liver, while liposarcoma returns mainly in the abdomen, so the same scan result can mean a different plan for each. That is also why the pathologist who reads the biopsy matters so much, because telling a well-differentiated liposarcoma from normal fat, or spotting a dedifferentiated area inside it, needs a specialist eye and sometimes a genetic test of the tumor cells. Get it right first. If a biopsy was already done at home, send the slides or the paraffin blocks with the report, so that our pathologists can review the original material instead of relying on a summary written for a different purpose. It costs nothing.
Before any operation
Core needle biopsy through the back, guided by CT or ultrasound, gives the diagnosis without spilling tumor cells into the abdomen.
Scans and planning
Contrast CT of the chest, abdomen and pelvis maps the tumor, its contact with the kidney, colon, psoas muscle, major vessels and nerves, and checks the lungs and liver for spread. A split kidney function scan is needed when the kidney may have to come out with the tumor. The tumor board, with surgical oncology, radiology, pathology, medical and radiation oncology at the same table, agrees the plan before a date is set, because sarcoma care depends on that coordination. Expect the full workup to take three to five days in Istanbul if nothing has been done at home, and less when recent scans and a confirmed biopsy arrive with you, since the board can then meet on the day after your arrival and the operation can follow within the same week. Plan for both. Bring every earlier scan you have, even old ones. Growth over months tells the surgeon a lot.
CT images on a download link or disc, the biopsy report and slides if a biopsy was done, and a list of any previous abdominal operations.
Why the center matters
Using the US National Cancer Database, a 2018 analysis grouped 3,803 operated patients by how many retroperitoneal sarcomas each hospital treated in a year.
On a phone, swipe the table sideways to see every column.
| Cases a year | Death within 30 days | Clear margins | Five-year survival |
|---|---|---|---|
| Fewer than 5 | 2.4 percent | 68 percent | 56 percent |
| 5 to 10 | 1.3 percent | 65 percent | 57 percent |
| More than 10 | 0.5 percent | 82 percent | 66 percent |
Any center you consider should be able to tell you how many retroperitoneal sarcomas its team operates on each year, and who reads the pathology.
How the operation runs
Across 249 patients treated at two European reference centers, reported in the Annals of Surgical Oncology in 2010, the median tumor measured 17 cm and a median of two organs came out with it. Removal of all visible tumor succeeded in 93 percent. Four to eight hours in theater. Then one to two nights in intensive care.
Risks of a large resection
What the 2010 series recorded
- 18 percent of patients needed at least one invasive procedure to treat a complication.
- 12 percent needed a second operation.
- 3 percent died of postoperative complications.
- Risk rose when more than three organs were removed.
Complications did not worsen the cancer outcome. Leaks at a bowel join, bleeding, infection, slow return of bowel function, numbness or weakness in the thigh when the psoas or its nerves are involved, and blood clots are the problems the team watches for. After one kidney is removed, the other takes over the work, and kidney function is checked before discharge. Most of these problems are managed on the ward with drains, antibiotics or a stent placed by an interventional radiologist, and only a minority need a return to theater, which in the 2010 series meant 12 percent of patients. Recovery from an operation of this size is measured in weeks rather than days, and most of the tiredness, poor appetite and stiffness of the first month fade steadily as walking distance grows and normal meals return, so the plan includes time to rebuild strength before the flight home.
Radiotherapy and chemotherapy
The STRASS trial
Swipe sideways on a small screen to read both arms of the trial.
| Measure | Radiotherapy, then surgery | Surgery alone |
|---|---|---|
| Median time free of abdominal recurrence | 4.5 years | 5.0 years |
| Serious adverse events | 24 percent | 10 percent |
STRASS concluded that preoperative radiotherapy should not be standard treatment. Not routine, then. It remains a case-by-case option discussed at the tumor board, and Biruni Hospital delivers it on an Elekta Versa HD linear accelerator when the board recommends it. Chemotherapy is used selectively, for high-grade tumors or disease that has spread, and is given by the medical oncology team on the same campus.
Weeks in Istanbul
On a narrow screen, drag the timeline sideways.
| When | What happens |
|---|---|
| Days 1 to 3 | Clinic visit, any missing scans, anesthesia review, tumor board |
| Surgery and ward | One to two nights in intensive care, then seven to twelve nights on the ward |
| Hotel week | Walking, wound and drain checks, blood tests |
| Weeks 3 to 4 | Final pathology with the tumor board, fitness to fly confirmed, flight home |
After you go home
Follow-up scans
CT scans of the chest, abdomen and pelvis continue for years, every three to six months in the first two to three years and less frequently after that, with closer checks for high-grade tumors. In the 2016 series, local recurrence reached 25.9 percent at five years and 35 percent at ten. Late returns are typical of well-differentiated liposarcoma. Keep the scans going. Follow-up continues once you are back home. Your coordinator on WhatsApp passes each report on, and the surgeon replies with a written opinion for your doctor.
If it comes back
Local recurrence found early can be removed again when the scan shows it is safe. Send the new scan as soon as it is done.
Travel and support
Your coordinator, assigned from the first message, works in English, Arabic, French, Russian, Serbian, Romanian or Spanish and arranges interpreters for other languages. Ten days before travel the international patients office sends an appointment confirmation and a visa invitation letter, then books the airport transfer, every trip between hotel and hospital, and a hotel for you and your companion before and after the admission. One office handles it all. One companion sleeps in your room on the ward. Halal, vegetarian and diabetic meals come from the hospital kitchen, and there is a prayer room on site.
Cost and what a quote covers
Quotes differ. Cost follows the number of organs removed, any vascular graft, the nights in intensive care and on the ward, and blood products drive the total. Published Istanbul packages for complex sarcoma surgery list the resection, pathology, blood units and around two weeks in hospital, and leave flights and hotel outside. Radiotherapy or chemotherapy, if recommended, is a separate plan, and a written quote that names the resection, the intensive care nights, the ward nights, the pathology and the blood products lets two hospitals be compared on the same terms. Request one, then compare.
Retroperitoneal sarcoma FAQ
Will I lose a kidney?
Can this be done with keyhole or robotic surgery?
Do I need radiotherapy before surgery?
How long do I stay in Istanbul?
References
- Gronchi A, Strauss DC, Miceli R, Bonvalot S, Swallow CJ, Hohenberger P, et al. Variability in Patterns of Recurrence After Resection of Primary Retroperitoneal Sarcoma (RPS). A Report on 1007 Patients From the Multi-institutional Collaborative RPS Working Group. Ann Surg. 2016;263(5):1002-1009.
- Bonvalot S, Miceli R, Berselli M, et al. Aggressive surgery in retroperitoneal soft tissue sarcoma carried out at high-volume centers is safe and is associated with improved local control. Ann Surg Oncol. 2010;17(6):1507-1514.
- Bonvalot S, Gronchi A, Le Péchoux C, et al. Preoperative radiotherapy plus surgery versus surgery alone for patients with primary retroperitoneal sarcoma (EORTC-62092, STRASS). A multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2020;21(10):1366-1377.
- Bagaria SP, Neville M, Gray RJ, Gabriel E, Ashman JB, Attia S, Wasif N. The Volume-Outcome Relationship in Retroperitoneal Soft Tissue Sarcoma. Evidence of Improved Short- and Long-Term Outcomes at High-Volume Institutions. Sarcoma. 2018;2018:3056562.
Editor's note
Written by the Biruni Hospital medical editorial team. Reviewed by Prof. Dr. Mustafa Teoman YANMAZ, Medical Oncology.
Medically reviewed by
Prof. Dr. Mustafa Teoman YANMAZ
Medical Oncology
Last updated: